The Diabetes Clinic at Steno Diabetes Center Odense, Denmark, has begun an evaluation of the VibroSense Meter® II with Diabetic Foot Screening as part of testing a new process to optimize patient flow.
Steno Diabetes Center, Odense has started a project to optimize patient flow as part of implementing a "One Stop Shop" concept, with the aim of minimizing the number of hospital visits for regular health checks of people living with diabetes.
The Diabetes Clinic, Skåne University Hospital in Lund has decided to introduce Diabetic Foot Screening as standard in the clinical operations, for regular control of nerve damage in the feet of people living with diabetes.
The diabetes clinic at Skåne University Hospital in Lund uses the VibroSense Meter® II and introduces the Diabetic Foot Screening examination as standard in its clinical operations. At the clinic, the methodology will be used in foot examinations of people living with diabetes.
In a publication on Plos One, the results of a clinical study were reported in which the company's technology Multi Frequency Vibrometry (MFV) was compared with Nerve Conduction Studies (NCS), which is generally regarded as the Gold Standard in the diagnosis of nerve damage caused by diabetes. The publication shows that there is a strong connection between MFV and NCS.
The company's patent application "CIPN Prediction ", to assess the risk of developing permanent nerve damage when treating cancer with chemotherapy, is published by the European Patent Office EPO on January 3, 2024. With the publication of the application, the company has a "provisional protection" for patent infringement.
After extensive testing in China and compilation of the required documentation, VibroSense has submitted an application for regulatory approval for the Company's product VibroSense Meter® II, to the Chinese authority National Medical Products Administration (NMPA).
VibroSense has signed a collaboration agreement regarding research on diabetes-related nerve damage with Professor Mitra Tavalkoli at the University of Exeter, Center of Excellence for Diabetes Research in the UK.
Professor Tavakoli intends to introduce and evaluate the VibroSense Meter® II in ongoing clinical studies on people with diabetes. The aim is to investigate whether the VibroSense instrument can be a tool for early and reliable detection of nerve damage caused by diabetes (Diabetic Peripheral Neuropathy).
Diabetic Foot Screening is introduced at the Insurance Clinic at Sophiahemmet as standard procedure in the clinical operations, for regular control of nerve damage in the feet of people living with diabetes. They are the first private healthcare provider in Sweden to use the method.
The Diabetes Clinic Herz und Diabetescentrum Nordrhein-Westfalen (HDZ NRW) has purchased VibroSense Meter® II and Diabetic Foot Screening after completed evaluation.
The clinic has been evaluating VibroSense Meter® II and the application Diabetic Foot Screening with a stated goal of purchasing the instrument after the evaluation is completed, provided that the instrument meets defined requirements. The order value is 16 500 EUR including an annual recurring software license fee of 2 000 EUR.
VibroSense Dynamics AB (VibroSense) - Several positive signs from the market as the Company continues to implement its business plan.
The business plan is continuously implemented with several actions in parallel. VibroSense has carried out various market activities and supported its customers as well as partners in multiple research studies. VibroSense has also identified that there is a pronounced interest in Sweden among people living with diabetes, to pay themselves for a reliable foot examination outside the public health care system.
The diabetes clinic “Herz- und Diabeteszentrum Nordrhein-Westfalen” (HDZ NRW) evaluates the instrument VibroSense Meter ® II with a planned start on September 22, 2022.
The diabetes clinic at HDZ NRW is a top-ranked clinic at the university hospital in Bochum in Germany. For the past two years (2020 and 2022), the clinic has received the highly regarded award "5-Sterne-Auszeichnung" awarded by the institute "Bundesverband Klinischer Diabetes- Einrichtungen ” (BKvD).
